Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2024-04-28 Annual Report
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled '2023 ANNUAL REPORT' and contains a detailed table of contents including sections such as Chairman's Statement, Financial Summary, Management Discussion and Analysis, Biographies of Directors and Senior Management, Corporate Governance Report, Report of Directors, Independent Auditor's Report, and multiple consolidated financial statements with notes. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with a comprehensive yearly report covering company activity and full financial performance, which matches the definition of an Annual Report (10-K). FY 2023
2024-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 March 2024. It details movements in authorized/registered share capital, issued shares, share options, and confirms compliance with listing rules. The content is regulatory in nature, reporting share capital and share issuance movements to the Hong Kong Exchanges and Clearing Limited. It does not contain financial statements, management discussion, earnings data, or audit information. It is a regulatory compliance filing specific to share capital movements and confirmations, fitting the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-08 English
GRANT OF SHARE OPTIONS
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of share options under the company's 2023 Share Option Scheme. It details the number of options granted, exercise price, vesting period, performance targets, and the identities of grantees including directors. The document references compliance with Listing Rules and includes no financial statements or comprehensive financial data. It is a regulatory announcement about share option grants, not a full financial report or management discussion. This fits the category of a Regulatory Filing (RNS) as it is a formal disclosure required by the stock exchange rules but does not constitute a financial report or other specific filing type.
2024-04-05 English
CLARIFICATION ANNOUNCEMENT REGARDING THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Regulatory Filings Classification · 95% confidence The document is titled as a "Clarification Announcement Regarding the Annual Results Announcement for the Year Ended December 31, 2023." It references a prior announcement dated March 28, 2024, concerning the annual results. The content mainly provides corrections and clarifications to previously disclosed financial and business development information. The document is relatively short (3121 characters) and serves as a supplemental announcement rather than the full annual report or earnings release itself. It does not contain full financial statements or comprehensive analysis but clarifies parts of the earlier announcement. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement or clarification that does not constitute the full report itself.
2024-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023' and contains detailed audited consolidated financial statements, including revenue, cost of sales, gross profit, research and development expenses, selling and marketing expenses, and comprehensive loss figures for the full fiscal year 2023. It also includes business highlights, pipeline updates, and management discussion and analysis sections. The length is substantial (15,000 characters), and the content includes actual financial data and analysis rather than just an announcement or summary. The document is not merely announcing the release of a report but contains the report itself. Therefore, it fits the definition of an Annual Report (10-K) rather than an Earnings Release or Report Publication Announcement. The presence of audited consolidated financial statements and comprehensive management discussion confirms this classification. FY 2023
2024-03-28 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from 3D Medicines Inc. regarding the date of a Board meeting to consider and approve the audited annual results for the financial year ended December 31, 2023, and the potential payment of a final dividend. The document does not contain any financial data or the actual report but merely announces the upcoming meeting and the agenda. The document length is short (1424 characters) and fits the pattern of a report publication announcement or meeting notice rather than the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2024-03-18 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.